Innovations in exosome isolation techniques, such as ultracentrifugation, immunoaffinity capture, and microfluidics, are enhancing the efficiency, yield, and purity of exosome isolation, making the process more viable for clinical applications. WILMINGTON, Del. , July 15, 2024 /PRNewswire/ -- The exoscome isolation market was projected to attain US$ 370.

7 million in 2023. It is likely to garner an 11.6% CAGR from 2024 to 2034, and by 2034, the market is expected to attain US$ 1.

2 billion . The trend towards personalized medicine, which involves tailoring treatment based on individual patient characteristics, is driving the demand for exosome-based diagnostics and therapeutics due to their potential in providing personalized treatment options. Progress in technologies like next-generation sequencing (NGS), proteomics, and advanced microscopy is facilitating better characterization and understanding of exosomes, propelling their use in various applications.

Exosomes are increasingly being integrated with liquid biopsy techniques for non-invasive cancer diagnostics and monitoring. This trend is expected to significantly drive market growth due to the rising adoption of liquid biopsies. The development and clinical trials of exosome-based therapeutics are gaining momentum.

These therapeutics are being explored for a range of applications, including targeted drug delivery and regenerative medicine. The introduction of automated and high-throughput exosome isolation systems is stre.